Skip to main content
Top
Published in: Critical Care 6/2014

Open Access 01-12-2014 | Review

A systematic review of adult admissions to ICUs related to adverse drug events

Authors: Pierre-Alain Jolivot, Patrick Hindlet, Claire Pichereau, Christine Fernandez, Eric Maury, Bertrand Guidet, Gilles Hejblum

Published in: Critical Care | Issue 6/2014

Login to get access

Abstract

Adverse drug events (ADE) may lead to hospital admission, and in some cases admission to an ICU is mandatory. We conducted a systematic review dealing with the incidence of ADE requiring ICU admission in adult patients, the reference population being all ICU admissions. Medline, Embase and Web of Science databases were screened from January 1982 to July 2014, using appropriate key words. Only original articles in English reporting the incidence of ADE requiring ICU admission in adult patients among total ICU admissions were included. Article eligibility was assessed by two independent reviewers, a third being involved in cases of disagreement. All reported characteristics (type of ICU, characteristics of patients, incidence of ADE, severity and preventability, drugs involved, causality) in the selected articles were collected for the review. The quality of studies was independently assessed by two reviewers with a specific score that we developed. A meta-analysis was conducted. Inclusion criteria were fulfilled by 11 studies out of the 4,311 identified in the initial literature search. The median (interquartile) quality score was 0.61 (0.44; 0.69). The reported incidences of ADE requiring ICU admission in adult patients ranged from 0.37 to 27.4%, with an associated mortality rate ranging from 2 to 28.1% and a mean length of stay ranging from 2.3 to 6.4 days. Preventable events accounted for 17.5 to 85.7% of the events. Costs and mechanisms at the root of ADE were investigated in only two and five studies, respectively. The forest plot examining the incidence of ADE requiring ICU admission in adult patients was associated with high heterogeneity (I 2 statistic >98%), and the shape of the corresponding funnel plot was asymmetric. Heterogeneity across studies concerned many features, including studied populations, events considered, causality assessment methods, definitions of preventability and severity. Despite the heterogeneity of the reports, our review indicates that ICU admission due to ADE is a significant issue that should deserve further interest. The review led us to propose a list of items devoted to the reporting of future studies on ADE requiring ICU admissions.
Appendix
Available only for authorised users
Literature
1.
go back to reference Kongkaew C, Noyce PR, Ashcroft DM: Hospital admissions associated with adverse drug reactions: a systematic review of prospective observational studies. Ann Pharmacother. 2008, 42: 1017-1025. 10.1345/aph.1L037.CrossRef Kongkaew C, Noyce PR, Ashcroft DM: Hospital admissions associated with adverse drug reactions: a systematic review of prospective observational studies. Ann Pharmacother. 2008, 42: 1017-1025. 10.1345/aph.1L037.CrossRef
2.
go back to reference Evans TW, Nava S, Mata GV, Guidet B, Estenssoro E, Fowler R, Scheunemann LP, White D, Manthous CA: Critical care rationing: international comparisons. Chest. 2011, 140: 1618-1624. 10.1378/chest.11-0957.CrossRef Evans TW, Nava S, Mata GV, Guidet B, Estenssoro E, Fowler R, Scheunemann LP, White D, Manthous CA: Critical care rationing: international comparisons. Chest. 2011, 140: 1618-1624. 10.1378/chest.11-0957.CrossRef
3.
go back to reference Rhodes A, Ferdinande P, Flaatten H, Guidet B, Metnitz PG, Moreno RP: The variability of critical care bed numbers in Europe. Intensive Care Med. 2012, 38: 1647-1653. 10.1007/s00134-012-2627-8.CrossRef Rhodes A, Ferdinande P, Flaatten H, Guidet B, Metnitz PG, Moreno RP: The variability of critical care bed numbers in Europe. Intensive Care Med. 2012, 38: 1647-1653. 10.1007/s00134-012-2627-8.CrossRef
4.
go back to reference Nebeker JR, Barach P, Samore MH: Clarifying adverse drug events: a clinician’s guide to terminology, documentation, and reporting. Ann Intern Med. 2004, 140: 795-801. 10.7326/0003-4819-140-10-200405180-00017.CrossRef Nebeker JR, Barach P, Samore MH: Clarifying adverse drug events: a clinician’s guide to terminology, documentation, and reporting. Ann Intern Med. 2004, 140: 795-801. 10.7326/0003-4819-140-10-200405180-00017.CrossRef
7.
go back to reference Vandenbroucke JP, von Elm E, Altman DG, Gotzsche PC, Mulrow CD, Pocock SJ, Poole C, Schlesselman JJ, Egger M: Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. PLoS Med. 2007, 4: e297-10.1371/journal.pmed.0040297.CrossRef Vandenbroucke JP, von Elm E, Altman DG, Gotzsche PC, Mulrow CD, Pocock SJ, Poole C, Schlesselman JJ, Egger M: Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. PLoS Med. 2007, 4: e297-10.1371/journal.pmed.0040297.CrossRef
8.
go back to reference Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D: The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009, 339: b2700-10.1136/bmj.b2700.CrossRef Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D: The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009, 339: b2700-10.1136/bmj.b2700.CrossRef
9.
go back to reference Schwarzer G: meta: an R package for meta-analysis. R News. 2007, 7: 40-45. Schwarzer G: meta: an R package for meta-analysis. R News. 2007, 7: 40-45.
10.
go back to reference Trunet P, Borda IT, Rouget AV, Rapin M, Lhoste F: The role of drug-induced illness in admissions to an intensive care unit. Intensive Care Med. 1986, 12: 43-46. 10.1007/BF00315371.CrossRef Trunet P, Borda IT, Rouget AV, Rapin M, Lhoste F: The role of drug-induced illness in admissions to an intensive care unit. Intensive Care Med. 1986, 12: 43-46. 10.1007/BF00315371.CrossRef
11.
go back to reference Epidemiology of adverse drug reactions in intensive care units: a multicentre prospective survey. Eur J Clin Pharmacol. 1987, 31: 507-512. 10.1007/BF00606621. Epidemiology of adverse drug reactions in intensive care units: a multicentre prospective survey. Eur J Clin Pharmacol. 1987, 31: 507-512. 10.1007/BF00606621.
12.
go back to reference Nelson KM, Talbert RL: Drug-related hospital admissions. Pharmacotherapy. 1996, 16: 701-707. Nelson KM, Talbert RL: Drug-related hospital admissions. Pharmacotherapy. 1996, 16: 701-707.
13.
go back to reference Darchy B, Le Miere E, Figueredo B, Bavoux E, Domart Y: Iatrogenic diseases as a reason for admission to the intensive care unit: incidence, causes, and consequences. Arch Intern Med. 1999, 159: 71-78. 10.1001/archinte.159.1.71.CrossRef Darchy B, Le Miere E, Figueredo B, Bavoux E, Domart Y: Iatrogenic diseases as a reason for admission to the intensive care unit: incidence, causes, and consequences. Arch Intern Med. 1999, 159: 71-78. 10.1001/archinte.159.1.71.CrossRef
14.
go back to reference Hammerman H, Kapeliovich M: Drug-related cardiac iatrogenic illness as the cause for admission to the intensive cardiac care unit. Isr Med Assoc J. 2000, 2: 577-579. Hammerman H, Kapeliovich M: Drug-related cardiac iatrogenic illness as the cause for admission to the intensive cardiac care unit. Isr Med Assoc J. 2000, 2: 577-579.
15.
go back to reference Lehmann LS, Puopolo AL, Shaykevich S, Brennan TA: Iatrogenic events resulting in intensive care admission: frequency, cause, and disclosure to patients and institutions. Am J Med. 2005, 118: 409-413. 10.1016/j.amjmed.2005.01.012.CrossRef Lehmann LS, Puopolo AL, Shaykevich S, Brennan TA: Iatrogenic events resulting in intensive care admission: frequency, cause, and disclosure to patients and institutions. Am J Med. 2005, 118: 409-413. 10.1016/j.amjmed.2005.01.012.CrossRef
16.
go back to reference Grenouillet-Delacre M, Verdoux H, Moore N, Haramburu F, Miremont-Salame G, Etienne G, Robinson P, Gruson D, Hilbert G, Gabinski C, Begaud B, Molimard M: Life-threatening adverse drug reactions at admission to medical intensive care: a prospective study in a teaching hospital. Intensive Care Med. 2007, 33: 2150-2157. 10.1007/s00134-007-0787-8.CrossRef Grenouillet-Delacre M, Verdoux H, Moore N, Haramburu F, Miremont-Salame G, Etienne G, Robinson P, Gruson D, Hilbert G, Gabinski C, Begaud B, Molimard M: Life-threatening adverse drug reactions at admission to medical intensive care: a prospective study in a teaching hospital. Intensive Care Med. 2007, 33: 2150-2157. 10.1007/s00134-007-0787-8.CrossRef
17.
go back to reference Rivkin A: Admissions to a medical intensive care unit related to adverse drug reactions. Am J Health Syst Pharm. 2007, 64: 1840-1843. 10.2146/ajhp060641.CrossRef Rivkin A: Admissions to a medical intensive care unit related to adverse drug reactions. Am J Health Syst Pharm. 2007, 64: 1840-1843. 10.2146/ajhp060641.CrossRef
18.
go back to reference Schwake L, Wollenschlager I, Stremmel W, Encke J: Adverse drug reactions and deliberate self-poisoning as cause of admission to the intensive care unit: a 1-year prospective observational cohort study. Intensive Care Med. 2009, 35: 266-274. 10.1007/s00134-008-1250-1.CrossRef Schwake L, Wollenschlager I, Stremmel W, Encke J: Adverse drug reactions and deliberate self-poisoning as cause of admission to the intensive care unit: a 1-year prospective observational cohort study. Intensive Care Med. 2009, 35: 266-274. 10.1007/s00134-008-1250-1.CrossRef
19.
go back to reference Mercier E, Giraudeau B, Ginies G, Perrotin D, Dequin PF: Iatrogenic events contributing to ICU admission: a prospective study. Intensive Care Med. 2010, 36: 1033-1037. 10.1007/s00134-010-1793-9.CrossRef Mercier E, Giraudeau B, Ginies G, Perrotin D, Dequin PF: Iatrogenic events contributing to ICU admission: a prospective study. Intensive Care Med. 2010, 36: 1033-1037. 10.1007/s00134-010-1793-9.CrossRef
20.
go back to reference Nazer LH, Eljaber R, Rimawi D, Hawari FI: Adverse drug events resulting in admission to the intensive care unit in oncology patients: incidence, characteristics and associated cost. J Oncol Pharm Pract. 2013, 19: 298-304. 10.1177/1078155212465995.CrossRef Nazer LH, Eljaber R, Rimawi D, Hawari FI: Adverse drug events resulting in admission to the intensive care unit in oncology patients: incidence, characteristics and associated cost. J Oncol Pharm Pract. 2013, 19: 298-304. 10.1177/1078155212465995.CrossRef
21.
go back to reference Trunet P, Le Gall JR, Lhoste F, Regnier B, Saillard Y, Carlet J, Rapin M: The role of iatrogenic disease in admissions to intensive care. JAMA. 1980, 244: 2617-2620. 10.1001/jama.1980.03310230019015.CrossRef Trunet P, Le Gall JR, Lhoste F, Regnier B, Saillard Y, Carlet J, Rapin M: The role of iatrogenic disease in admissions to intensive care. JAMA. 1980, 244: 2617-2620. 10.1001/jama.1980.03310230019015.CrossRef
22.
go back to reference Bates DW, Cullen DJ, Laird N, Petersen LA, Small SD, Servi D, Laffel G, Sweitzer BJ, Shea BF, Hallisey R, Vander Vliet M, Nemeskal R, Leape LL: Incidence of adverse drug events and potential adverse drug events: implications for prevention ADE Prevention Study Group. JAMA. 1995, 274: 29-34. 10.1001/jama.1995.03530010043033.CrossRef Bates DW, Cullen DJ, Laird N, Petersen LA, Small SD, Servi D, Laffel G, Sweitzer BJ, Shea BF, Hallisey R, Vander Vliet M, Nemeskal R, Leape LL: Incidence of adverse drug events and potential adverse drug events: implications for prevention ADE Prevention Study Group. JAMA. 1995, 274: 29-34. 10.1001/jama.1995.03530010043033.CrossRef
23.
go back to reference Lindquist M, Edwards IR: The WHO Programme for International Drug Monitoring, its database, and the technical support of the Uppsala Monitoring Center. J Rheumatol. 2001, 28: 1180-1187. Lindquist M, Edwards IR: The WHO Programme for International Drug Monitoring, its database, and the technical support of the Uppsala Monitoring Center. J Rheumatol. 2001, 28: 1180-1187.
24.
go back to reference Schumock GT, Thornton JP: Focusing on the preventability of adverse drug reactions. Hosp Pharm. 1992, 27: 538- Schumock GT, Thornton JP: Focusing on the preventability of adverse drug reactions. Hosp Pharm. 1992, 27: 538-
25.
go back to reference Kramer MS, Leventhal JM, Hutchinson TA, Feinstein AR: An algorithm for the operational assessment of adverse drug reactions. I. Background, description, and instructions for use. JAMA. 1979, 242: 623-632. 10.1001/jama.1979.03300070019017.CrossRef Kramer MS, Leventhal JM, Hutchinson TA, Feinstein AR: An algorithm for the operational assessment of adverse drug reactions. I. Background, description, and instructions for use. JAMA. 1979, 242: 623-632. 10.1001/jama.1979.03300070019017.CrossRef
27.
go back to reference Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, Janecek E, Domecq C, Greenblatt DJ: A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981, 30: 239-245. 10.1038/clpt.1981.154.CrossRef Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, Janecek E, Domecq C, Greenblatt DJ: A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981, 30: 239-245. 10.1038/clpt.1981.154.CrossRef
28.
go back to reference Karch FE, Lasagna L: Toward the operational identification of adverse drug reactions. Clin Pharmacol Ther. 1977, 21: 247-254.CrossRef Karch FE, Lasagna L: Toward the operational identification of adverse drug reactions. Clin Pharmacol Ther. 1977, 21: 247-254.CrossRef
29.
go back to reference Hallas J, Harvald B, Gram LF, Grodum E, Brosen K, Haghfelt T, Damsbo N: Drug related hospital admissions: the role of definitions and intensity of data collection, and the possibility of prevention. J Intern Med. 1990, 228: 83-90. 10.1111/j.1365-2796.1990.tb00199.x.CrossRef Hallas J, Harvald B, Gram LF, Grodum E, Brosen K, Haghfelt T, Damsbo N: Drug related hospital admissions: the role of definitions and intensity of data collection, and the possibility of prevention. J Intern Med. 1990, 228: 83-90. 10.1111/j.1365-2796.1990.tb00199.x.CrossRef
30.
go back to reference Begaud B, Evreux JC, Jouglard J, Lagier G: Imputation of the unexpected or toxic effects of drugs: Actualization of the method used in France. Therapie. 1985, 40: 111-118. Begaud B, Evreux JC, Jouglard J, Lagier G: Imputation of the unexpected or toxic effects of drugs: Actualization of the method used in France. Therapie. 1985, 40: 111-118.
31.
go back to reference Vlayen A, Verelst S, Bekkering GE, Schrooten W, Hellings J, Claes N: Incidence and preventability of adverse events requiring intensive care admission: a systematic review. J Eval Clin Pract. 2012, 18: 485-497. 10.1111/j.1365-2753.2010.01612.x.CrossRef Vlayen A, Verelst S, Bekkering GE, Schrooten W, Hellings J, Claes N: Incidence and preventability of adverse events requiring intensive care admission: a systematic review. J Eval Clin Pract. 2012, 18: 485-497. 10.1111/j.1365-2753.2010.01612.x.CrossRef
32.
go back to reference Hakkarainen KM, Andersson Sundell K, Petzold M, Hagg S: Methods for assessing the preventability of adverse drug events: a systematic review. Drug Saf. 2012, 35: 105-126. 10.2165/11596570-000000000-00000.CrossRef Hakkarainen KM, Andersson Sundell K, Petzold M, Hagg S: Methods for assessing the preventability of adverse drug events: a systematic review. Drug Saf. 2012, 35: 105-126. 10.2165/11596570-000000000-00000.CrossRef
33.
go back to reference Kane-Gill SL, Forsberg EA, Verrico MM, Handler SM: Comparison of three pharmacovigilance algorithms in the ICU setting: a retrospective and prospective evaluation of ADRs. Drug Saf. 2012, 35: 645-653. 10.1007/BF03261961.CrossRef Kane-Gill SL, Forsberg EA, Verrico MM, Handler SM: Comparison of three pharmacovigilance algorithms in the ICU setting: a retrospective and prospective evaluation of ADRs. Drug Saf. 2012, 35: 645-653. 10.1007/BF03261961.CrossRef
34.
go back to reference Queneau P, Bannwarth B, Carpentier F, Guliana JM, Bouget J, Trombert B, Leverve X, Lapostolle F, Borron SW, Adnet F: Emergency department visits caused by adverse drug events: results of a French survey. Drug Saf. 2007, 30: 81-88. 10.2165/00002018-200730010-00008.CrossRef Queneau P, Bannwarth B, Carpentier F, Guliana JM, Bouget J, Trombert B, Leverve X, Lapostolle F, Borron SW, Adnet F: Emergency department visits caused by adverse drug events: results of a French survey. Drug Saf. 2007, 30: 81-88. 10.2165/00002018-200730010-00008.CrossRef
35.
go back to reference Trinh-Duc A, Doucet J, Bannwarth B, Trombert-Paviot B, Carpentier F, Bouget J, Queneau P: Admissions of elderly to French emergency departments related to adverse drug events. Therapie. 2007, 62: 437-441. 10.2515/therapie:2007063.CrossRef Trinh-Duc A, Doucet J, Bannwarth B, Trombert-Paviot B, Carpentier F, Bouget J, Queneau P: Admissions of elderly to French emergency departments related to adverse drug events. Therapie. 2007, 62: 437-441. 10.2515/therapie:2007063.CrossRef
36.
go back to reference Chen YC, Fan JS, Hsu TF, Chen MH, Huang HH, Cheng KW, Yen DH, Huang MS, Lee CH, Chen LK, Yang CC: Detection of patients presenting with adverse drug events in the emergency department. Intern Med J. 2012, 42: 651-657. 10.1111/j.1445-5994.2011.02684.x.CrossRef Chen YC, Fan JS, Hsu TF, Chen MH, Huang HH, Cheng KW, Yen DH, Huang MS, Lee CH, Chen LK, Yang CC: Detection of patients presenting with adverse drug events in the emergency department. Intern Med J. 2012, 42: 651-657. 10.1111/j.1445-5994.2011.02684.x.CrossRef
Metadata
Title
A systematic review of adult admissions to ICUs related to adverse drug events
Authors
Pierre-Alain Jolivot
Patrick Hindlet
Claire Pichereau
Christine Fernandez
Eric Maury
Bertrand Guidet
Gilles Hejblum
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Critical Care / Issue 6/2014
Electronic ISSN: 1364-8535
DOI
https://doi.org/10.1186/s13054-014-0643-5

Other articles of this Issue 6/2014

Critical Care 6/2014 Go to the issue